← All trials
NCT06145438
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 4, 2023
- Primary completion
- Mar 4, 2024
- Completion date
- Apr 4, 2024
- First posted
- Nov 24, 2023
- Last posted
- Nov 24, 2023
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Diponegoro UniversityLead sponsor
- Diponegoro UniversityReponsible party - principal investigator
- Diponegoro UniversityOfficial
- Diponegoro UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.